KRAS and colorectal cancer: As for attempts to detect genetic mutations by analyzing cfDNA in blood, what began as an assay to detect KRAS/BRAF mutations associated with resistance to EGFR antibody therapy in colorectal cancer patients has evolved into the development of a commercial panel test for a large cohort of more than 10,000 patients [28,29].